Cancer drug ruxolitinib keeps flowing to stable patients in rollover trial

NCT ID NCT02955940

Ongoing Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, and the main goal is to monitor safety and side effects, not to test new effectiveness. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib (a targeted cancer drug, also known as Jakafi), sometimes given with capecitabine or regorafenib
What this could lead to: If successful, this study helps ensure patients who are already benefiting from ruxolitinib can keep taking it without interruption, while gathering more safety data.
What could go wrong: This is a small rollover study (10 people) that does not test new effectiveness. It only continues existing treatment and monitors side effects, so it won't prove whether ruxolitinib works for these cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLORECTAL CANCER (CRC) LUNG CANCER PANCREATIC CANCER

Contacts and locations

Locations

Instytut Hematologii I Transfuzjologii

Warsaw, 02-776, Poland
New York Oncology Hematology Pc.

Clifton Park, New York, 12065, United States
Renovatio Clinical Consultants Llc

The Woodlands, Texas, 77380, United States
Samodzielny Publiczny Szpital Kliniczny

Lublin, 20-081, Poland
Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii

Krakow, 31-501, Poland
Tennessee Oncology

Nashville, Tennessee, 37203, United States
UCLA Healthcare Hematology-Oncology

Santa Monica, California, 90404, United States
University of Louisville

Louisville, Kentucky, 40202, United States
University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.